title: Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.
authors.affiliation: Service d'Oncologie Thoracique, Hôpital Arnaud de Villeneuve, Montpellier jl-pujol@chu-montpellier.fr.
authors.forename: J-L
authors.initials: JL
authors.lastname: Pujol
authors.affiliation: Data Center, French Cooperative Thoracic Intergroup (IFCT), Paris.
authors.forename: F
authors.initials: F
authors.lastname: Morin
authors.affiliation: Department of Pneumology, CHU Côte de Nacre, Caen, France.
authors.forename: G
authors.initials: G
authors.lastname: Zalcman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab